See more : Serendip Holdings Co.,Ltd. (7318.T) Income Statement Analysis – Financial Results
Complete financial analysis of Jounce Therapeutics, Inc. (JNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jounce Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Eagle Plains Resources Ltd. (EGPLF) Income Statement Analysis – Financial Results
- First Class Metals PLC (FCM.L) Income Statement Analysis – Financial Results
- Digital World Acquisition Corp. (DWAC) Income Statement Analysis – Financial Results
- Pacific Gas and Electric Company (PCG-PE) Income Statement Analysis – Financial Results
- Golden Nugget Online Gaming, Inc. (GNOG) Income Statement Analysis – Financial Results
Jounce Therapeutics, Inc. (JNCE)
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 103.27M | 88.98M | 78.69M | 67.14M | 70.05M | 67.80M | 34.90M | 22.13M | 11.24M |
| General & Administrative | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Other Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Cost & Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.09M | 2.83M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.11M |
| EBITDA | -50.16M | -91.06M | -45.12M | 52.82M | -23.50M | -11.99M | -11.76M | -27.06M | -9.41M |
| EBITDA Ratio | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% | -16.73% | -31.61% | 0.00% | 0.00% |
| Operating Income | -52.24M | -91.06M | -45.12M | 52.82M | -31.29M | -19.22M | -14.47M | -30.40M | -16.21M |
| Operating Income Ratio | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% | -26.82% | -38.89% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 3.96M | 2.81M | 763.00K | 1.86M | 5.70M |
| Income Before Tax | -50.78M | -90.86M | -43.83M | 56.87M | -27.33M | -16.41M | -13.70M | -28.53M | -10.52M |
| Income Before Tax Ratio | -61.93% | -337.67% | -70.31% | 38.46% | -41.92% | -22.90% | -36.84% | 0.00% | 0.00% |
| Income Tax Expense | 135.00K | 15.00K | 14.00K | 46.00K | 46.00K | 36.00K | 763.00K | 1.86M | 5.70M |
| Net Income | -50.92M | -90.87M | -43.84M | 56.82M | -27.38M | -16.44M | -13.70M | -28.53M | -10.52M |
| Net Income Ratio | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% | -22.95% | -36.84% | 0.00% | 0.00% |
| EPS | -0.99 | -1.82 | -1.24 | 1.72 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| Weighted Avg Shares Out | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
| Weighted Avg Shares Out (Dil) | 51.68M | 49.93M | 35.43M | 34.29M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 6) ADiTx Therapeutics Inc (NASDAQ: ADTX) (announced introduction of AditxtScore for COVID-19 to be used in detecting...
Jounce Therapeutics Inc (NASDAQ:JNCE) Shares Sold by Deutsche Bank AG
Deutsche Bank AG trimmed its holdings in shares of Jounce Therapeutics Inc (NASDAQ:JNCE) by 83.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned...
Stocks To Watch: Nike, Apple, Ford And Stressed Banks
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Jounce Therapeutics (JNCE) Investor Presentation - Slideshow
The following slide deck was published by Jounce Therapeutics, Inc. in conjunction with this event.
Massachusetts Financial Services Co. MA Purchases Shares of 282,955 Jounce Therapeutics Inc (NASDAQ:JNCE)
Massachusetts Financial Services Co. MA purchased a new stake in Jounce Therapeutics Inc (NASDAQ:JNCE) in the 1st quarter, according to its most recent filing with the SEC. The fund purchased 282,955 shares of the company’s stock, valued at approximately $1,344,000....
UAB Professor Co-Authors Study On Sex-Based Differences In Autoimmune Disease Susceptibility
The study says gene variants cause men and women to have different vulnerabilities to lupus and Sjögren's syndrome.
Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development
Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of
The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week Highs May 5) • Adverum Biotechnologies...
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Financial Survey: Jounce Therapeutics (NASDAQ:JNCE) vs. TRACON Pharmaceuticals (NASDAQ:TCON)
Jounce Therapeutics (NASDAQ:JNCE) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings and analyst recommendations....
Source: https://incomestatements.info
Category: Stock Reports